Medicago's Covid-19 vaccine triggers immune response in early-stage trial

Canadian drug developer Medicago said on Tuesday a combination of its experimental Covid-19 vaccine and GlaxoSmithKline’s vaccine booster produced virus-neutralizing antibodies in all healthy volunteers in an early-stage study.

from Hindustan Times - topnews https://ift.tt/3nfezyR